Research programme: anti-HIV agents - Quigley Pharma

Drug Profile

Research programme: anti-HIV agents - Quigley Pharma

Alternative Names: QR 437

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Quigley Pharma
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in USA
  • 16 Jul 2009 Preclinical trials in HIV infections in USA (unspecified route)
  • 02 Feb 2005 Preclinical trials in HIV infections prevention in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top